دورية أكاديمية
Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
العنوان: | Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results |
---|---|
المؤلفون: | Pouessel, Damien, Ken, Soléakhéna, Gouaze-Andersson, Valérie, Piram, Lucie, Mervoyer, Augustin, Larrieu-Ciron, Delphine, Cabarrou, Bastien, Lusque, Amélie, Robert, Marie, Frenel, Jean-Sebastien, Uro-Coste, Emmanuelle, Olivier, Pascale, Mounier, Muriel, Sabatini, Umberto, Sanchez, Eduardo Hugo, Zouitine, Mehdi, Berjaoui, Ahmad, Cohen-Jonathan Moyal, Elizabeth |
المساهمون: | Institut Claudius Regaud, ARC Foundation |
المصدر: | The Oncologist ; volume 28, issue 9, page 825-e817 ; ISSN 1083-7159 1549-490X |
بيانات النشر: | Oxford University Press (OUP) |
سنة النشر: | 2023 |
مصطلحات موضوعية: | Cancer Research, Oncology |
الوصف: | Background Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalumab combined with hFSRT in patients with recurrent GB. Methods Patients were treated with 24 Gy, 8 Gy per fraction on days 1, 3, and 5 combined with the first 1500 mg Durvalumab dose on day 5, followed by infusions q4weeks until progression or for a maximum of 12 months. A standard 3 + 3 Durvalumab dose de-escalation design was used. Longitudinal lymphocytes count, cytokines analyses on plasma samples, and magnetic resonance imaging (MRI) were collected. Results Six patients were included. One dose limiting toxicity, an immune-related grade 3 vestibular neuritis related to Durvalumab, was reported. Median progression-free interval (PFI) and overall survival (OS) were 2.3 and 16.7 months, respectively. Multi-modal deep learning-based analysis including MRI, cytokines, and lymphocytes/neutrophil ratio isolated the patients presenting pseudoprogression, the longest PFI and those with the longest OS, but statistical significance cannot be established considering phase I data only. Conclusion Combination of hFSRT and Durvalumab in recurrent GB was well tolerated in this phase I study. These encouraging results led to an ongoing randomized phase II. (ClinicalTrials.gov Identifier: NCT02866747). |
نوع الوثيقة: | article in journal/newspaper |
اللغة: | English |
DOI: | 10.1093/oncolo/oyad095 |
الإتاحة: | https://doi.org/10.1093/oncolo/oyad095Test https://academic.oup.com/oncolo/article-pdf/28/9/825/51758976/oyad095.pdfTest |
حقوق: | https://creativecommons.org/licenses/by-nc/4.0Test/ |
رقم الانضمام: | edsbas.A37367D3 |
قاعدة البيانات: | BASE |
DOI: | 10.1093/oncolo/oyad095 |
---|